Moreover, sequential administration of low-dose TSA and anti-PD-L1 have synergistic anti-cancer effects in syngeneic mouse models, suggesting that the combination therapy may benefit PD-L1-resistant patients in the clinic. The gene discussed is CD274; the disease is cancer.